Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy
Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known to reduce neovascularization and fibrovascular proliferation in inflammatory conditions, including post-operative inflammation. It has shown efficacy in numerous ocular conditions(off-label), that includes Age related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma and corneal neovascularization. It is being explored as an option for preventing recurrence of pterygium and as an adjunct to improving outcomes of trabeculectomy. There is a debate as to the mode and duration of bevacizumab administration for trabeculectomy. This study aims to compare a single subconjunctival dose of bevacizumab with topical therapy over one month in terms of outcomes of trabeculectomy surgery, non-progression of field loss and stable intraocular pressure(IOP) control.
Arms and Interventions
Depending upon the mode of administration
Surgery for complications of trabeculectomy
Primary Outcome Measures
- Intraocular pressure control [For 2 years]
Secondary Outcome Measures
- Progression [2 years]
Primary Open Angle Glaucoma
Failure to reach target IOP
Systemic contraindication to bevacizumab
All other forms of glaucoma
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- Sudhalkar Eye Hospital
Study Documents (Full-Text)None provided.